布伦妥昔单抗维多汀治疗激素难治性急性移植物抗宿主病的1期多中心试验
这项1期多中心试验在34例激素难治性急性移植物抗宿主病(SR-aGVHD)患者中确定布伦妥昔单抗维多汀(BV)的最大耐受剂量(MTD)。初始每周给药方案中6例有2例死于中性粒细胞减少性脓毒症并发症,后改为每2周给药方案。MTD为0.8 mg/kg,观察到1例剂量限制性毒性(脓毒症)。第28天总缓解率为38.2%,6个月和12个月总生存率分别为41%和38%。
要点
- BV每2周给药方案的最大耐受剂量为0.8 mg/kg,观察到1例剂量限制性毒性(脓毒症)。
- 第28天总缓解率为38.2%,其中完全缓解5例(14.7%),非常好的部分缓解8例(23.5%)。
- 12个月随访时,6个月总生存率为41%(95%CI 25%-57%),12个月总生存率为38%(95%CI 22%-54%)。
核心结论
- BV可耐受且在SR-aGVHD中具有活性,值得进一步研究。
研究设计与样本
- 多中心1期试验,采用3+3队列设计,共34例SR-aGVHD患者。
- 初始方案为BV每周×3次后维持给药(初始剂量0.6 mg/kg静脉 weekly),6例接受该方案。
- 试验修订后改为每2周×4次给药、剂量限制性毒性观察期4周的递增队列,每队列5例,28例接受每2周给药(0.6 mg/kg组10例;0.8 mg/kg组18例)。
主要发现
- 初始每周给药方案中6例有2例死于中性粒细胞减少性脓毒症并发症。
- 每2周给药方案中,MTD定义为0.8 mg/kg,观察到1例剂量限制性毒性(脓毒症)。
- 第28天总缓解率为38.2%,其中完全缓解5例(14.7%),非常好的部分缓解8例(23.5%)。
- 另有7例在第56天达到完全缓解。
- 全部患者随访12个月,6个月总生存率为41%(95%CI 25%-57%),12个月总生存率为38%(95%CI 22%-54%)。
关键数值与推荐
- BV每2周给药方案的最大耐受剂量为0.8 mg/kg。
- 第28天总缓解率为38.2%,完全缓解率14.7%,非常好的部分缓解率23.5%。
- 6个月总生存率41%(95%CI 25%-57%),12个月总生存率38%(95%CI 22%-54%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapy for steroid-refractory acute graft-versus-host disease (SR-aGVHD) remains suboptimal. Preclinical data demonstrate increased CD30 expression on activated CD8+ T cells during aGVHD. Brentuximab vedotin (BV) is an antibody-drug conjugate targeting CD30. We conducted a multicenter phase 1 trial in 34 patients to establish the maximum tolerated dose (MTD) of BV for SR-aGVHD treatment. A 3+3 cohort design was conducted initially with BV given weekly × 3 doses followed by maintenance dosing (initial dose 0.6 mg/kg IV weekly). Six patients were treated with the initial weekly dosing scheme; 2 of these patients died of neutropenic sepsis complications. The trial was subsequently revised to escalating cohorts of 5 patients treated every 2 weeks × 4 doses with a 4-week dose-limiting toxicity (DLT) period. Twenty-eight patients were treated with every-2-week dosing (n = 10 at 0.6 mg/kg; n = 18 at 0.8 mg/kg). MTD was defined at 0.8 mg/kg with 1 DLT observed (sepsis). At day 28, the overall response rate was 38.2% with 5 complete responses (CRs; 14.7%) and 8 very-good-partial responses (23.5%). An additional 7 patients achieved CR by day 56. With 12 months' follow-up on all patients, overall survival was 41% (95% confidence interval [CI], 25%-57%) at 6 months and 38% (95% CI, 22%-54%) at 12 months. CD30 expression on central memory CD8+, central memory CD4+, and regulatory T-lymphocyte subsets at enrollment was not associated with clinical response. BV is tolerable and has activity in SR-aGVHD and merits further investigation. This trial was registered at www.clinicaltrials.gov as #NCT01940796.
引用
- Chen YB, Perales MA, Li S, et al. Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease. Blood. 2017. PMID: 28473406. doi:10.1182/blood-2017-03-772210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。